Claims
- 1. A prostate-specific antigen (PSA) derived peptide that is capable of eliciting an immune response comprising a sequence of the Formula I:
- 2. A PSA derived peptide according to claim 1 selected from the group consisting of MWVPVVFL (SEQ ID NO: 1), VLVHPQWVL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3), or a fragment, analog, derivative or elongation of the PSA derived peptide.
- 3. A PSA derived peptide according to claim 1 selected from the group consisting of MWVVVFL (SEQ ID NO: 1), VLVHPQWVL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3).
- 4. A fusion protein comprising the PSA peptide as described in claim 1.
- 5. A nucleic acid molecule encoding a PSA derived peptide according to claim 1.
- 6. A nucleic acid molecule encoding a PSA derived peptide according to claim 5 comprising:
(a) a nucleic acid sequence as shown in any one of SEQ ID NOS:7-9 wherein T can also be U; (b) a nucleic acid sequence that is complementary to a nucleic acid sequence of (a); (c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b); (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or (e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.
- 7. A nucleic acid molecule encoding a PSA derived peptide according to claim 5 having a sequence selected from the group consisting of: SEQ ID NO:7; SEQ ID NO:8; and SEQ ID NO:9.
- 8. An expression vector comprising a nucleic acid molecule of claim 5 and regulatory sequences suitable for expression of the nucleic acid molecule.
- 9. A host cell transformed with an expression vector of claim 8.
- 10. A composition for eliciting an immune response in an animal comprising an effective amount of a peptide according to claim 1 in admixture with a suitable diluent or carrier.
- 11. The composition of claim 10 further comprising an adjuvant.
- 12. A composition for eliciting an immune response in an animal comprising an effective amount of a nucleic acid according to claim 5 in admixture with a suitable diluent or carrier.
- 13. The composition of claim 12 further comprising an adjuvant.
- 14. A method of eliciting an immune response in an animal comprising administering an effective amount of a peptide according to claim 1 to the animal.
- 15. A method of eliciting an immune response in an animal comprising administering an effective amount of a fusion protein according to claim 4 to the animal.
- 16. A method of eliciting an immune response in an animal comprising administering an effective amount of a nucleic acid molecule according to claim 5 to the animal.
- 17. A method of eliciting an immune response in an animal comprising administering an effective amount of a composition according to claim 10 to the animal.
- 18. A method of treating cancer comprising administering to an animal an effective amount of a peptide according to claim 1.
- 19. A method of treating cancer comprising administering to an animal an effective amount of a fusion protein according to claim 4.
- 20. A method of treating cancer comprising administering to an animal an effective amount of a nucleic acid molecule according to claim 5.
- 21. A method of treating cancer comprising administering to an animal an effective amount of a composition according to claim 10.
- 22. A method according to claim 18 wherein the cancer is prostate cancer.
Parent Case Info
[0001] The application claims benefit from U.S. Provisional Application Serial No. 60/195,456 filed Apr. 10, 2000 which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60195456 |
Apr 2000 |
US |